HK Stock Market Move | ALPHAMAB-B (09966) rose more than 8% during trading, with a mid-term company profit of 21.57 million yuan and an increase in research and development expenses.

ALPHAMAB-B (09966) rose by more than 8% during trading hours, with an increase of 8.86% at the time of writing, reaching HKD 10.08. The trading volume was HKD 181.95 million. On the news front, on August 28, ALPHAMAB-B released its interim performance for the six-month period ending June 30, 2025, with a revenue of RMB 319 million, an increase of 84.05% year-on-year. The company also reported a profit of RMB 21.575 million during the period, compared to a loss of RMB 44.896 million in the same period last year, turning from a loss to profit. Earnings per share were RMB 0.02. The announcement stated that the company's R&D expenses increased from RMB 194.5 million in the six months ending June 30, 2024, to RMB 253.2 million in the six months ending June 30, 2025, mainly due to an increase in the number of ongoing clinical trials, expansion of the clinical research scale, and progress in clinical trials of candidate drugs.